Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RXi expands into cancer immunotherapy through acquisition of MirImmune

Executive Summary

Exercising an option it gained through a 2015 alliance, RXi Pharmaceuticals Corp. has acquired privately held oncology immunotherapy company MirImmune Inc. MirImmune shareholders get 2.75mm RXi common shares, plus 1.1mm Series C preferred shares (convertible into 1.1mm common) and earn-outs.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Includes Earnout
    • Intra-Biotech Deal
    • Payment Includes Stock

Related Companies